Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia

Leukemia

Volumn 21, Issue 12, 2007, Pages 2495-2505

  Tonks, A ^a   Pearn, L ^a   Musson, M ^a   Gilkes, A ^a   Mills, K I ^a   Burnett, A K ^a   Darley, R L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CORE BINDING FACTOR; HYBRID PROTEIN; INTERLEUKIN 17; PLAKOGLOBIN; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; TRANSCRIPTION FACTOR SOX4; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINEAGE; CHROMOSOME 16; CHROMOSOME INVERSION; CONTROLLED STUDY; DNA FINGERPRINTING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; GRANULOCYTE PRECURSOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; STEM CELL; TRANSCRIPTION REGULATION;

EID: 36349010744     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404961     Document Type: Article

References (54)

1. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene 2004; 23: 4255-4262.
2. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12 2715-2721.
3. Wunderlich M, Krejci O, Wei J, Mulloy JC. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 2006; 108: 1690-1697.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
5. Reilly JT. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? Br J Haematol 2005; 128: 18-34.
6. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
7. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
8. Tonks A, Tonks AJ, Pearn L, Pearce L, Hoy T, Couzens S et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 2004; 18: 1238-1245.
9. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18: 7176-7184.
10. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
11. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene 1999; 18: 1701-1710.
12. Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, Tenen DG et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 1996; 93: 11895-11900.
13. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112: 1751-1761.
14. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-2904.
15. Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, Kitabayashi I et al. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: Overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 2000; 96: 655-663.
16. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
17. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535-3543.
18. Lennon G, Auffray C, Polymeropoulos M, Soares MB. The I.M.A.G.E. Consortium: An integrated molecular analysis of genomes and their expression. Genomics 1996; 33: 151-152.
19. Tonks A, Pearn L, Tonks AJ, Pearce L, Hoy T, Phillips S et al. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 2003; 101: 624-632.
20. Shimada H, Ichikawa H, Ohki M. Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis. Leukemia 2002; 16: 874-885.
21. Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 2005; 132 2263-2272.
22. Hellstrom I, Beaurdier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA 1986; 83: 7059-7063.
23. Dey A, Westphal H, Nebert DW. Cell-specific induction of mouse Cyp1a1 mRNA during development. Proc Natl Acad Sci USA 1989; 86: 7446-7450.
24. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
25. Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, Jenkins NA et al. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood 2006; 107: 733-741.
26. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679-3687.
27. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006; 103: 1041-1046.
28. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194-4197.
29. Schwarzenberger P, Kolls JK. Interleukin 17: An example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis. J Cell Biochem Suppl 2002; 38: 88-95.
30. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002; 23: 285-290.
31. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566-568.
32. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K et al. Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 2004; 23 964-972.
33. Nimer SD, Moore MA. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 2004; 23 4249-4254.
34. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998; 18: 322-333.
35. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/ EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
36. Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O et al. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA 2005; 102: 4016-4021.
37. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-174.
38. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T et al. Leukaemia disease genes: Large-scale cloning and pathway predictions. Nat Genet 1999; 23: 348-353.
39. Reichling T, Goss KH, Carson DJ, Holdcraft RW, Ley-Ebert C, Witte D et al. Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. Cancer Res 2005; 65: 166-176.
40. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171 3034-3046.
41. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
42. Charpentier E, Lavker RM, Acquista E, Cowin P. Plakoglobin suppresses epithelial proliferation and hair growth in vivo. J Cell Biol 2000; 149: 503-520.
43. Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze'ev A. Suppression of tumorigenicity by plakoglobin: An augmenting effect of N-cadherin. J Cell Biol 1996; 133: 199-209.
44. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 2005; 11 (Part 1): 557-564.
45. Polychronopoulou S, Tsatsopoulou A, Papadhimitriou SI, Panagiotou JP, Anastasakis A, Paterakis G et al. Myelodysplasia and Naxos disease: A novel pathogenetic association? Leukemia 2002; 16 2335-2337.
46. Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A tole for the Wnt gene family in hematopoiesis: Expansion of multilineage progenitor cells. Blood 1997; 89: 3624-3635.
47. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
48. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999; 96: 5522-5527.
49. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-2420.
50. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
51. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol 2000; 20: 4238-4252.
52. Zhurinsky I, Shtutman M, Ben-Ze'ev A. Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci 2000; 113 (Part 18): 3127-3139.
53. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004; 18: 2747-2763.
54. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.